GLIOBLASTOMA BIOMARKERS:
MGMT, IDH, AND WHAT THEY MEAN
Your brain tumour pathology report contains markers that define your diagnosis, predict treatment response, and determine eligibility for clinical trials โ this guide explains each one in plain language.
analyticsAt a Glance
- check_circleMGMT methylation is the most important biomarker in GBM โ it predicts whether temozolomide will extend your survival
- check_circleIDH mutation distinguishes true GBM (IDH-wildtype) from IDH-mutant gliomas which have much better prognosis
- check_circleH3K27M identifies diffuse midline gliomas (DMG) โ a separate entity from GBM requiring different treatment
- check_circle1p/19q co-deletion in IDH-mutant tumours confirms oligodendroglioma โ the most chemotherapy-sensitive brain tumour
MGMT Promoter Methylation: The Most Important GBM Biomarker
MGMT (O6-methylguanine-DNA methyltransferase) is a DNA repair enzyme. When its promoter is methylated, the gene is silenced โ meaning cancer cells cannot repair the DNA damage caused by temozolomide chemotherapy.
โMGMT methylation is the single most powerful predictor of temozolomide benefit in glioblastoma โ it is not optional testing.โ
MGMT Methylated (~45% of GBMs)
Temozolomide is significantly effective. Stupp protocol (RT + TMZ) gives median OS 21.7 months vs 12.7 months without TMZ in methylated tumours. Long-term survivors (>3 years) are almost exclusively MGMT-methylated.
MGMT Unmethylated (~55% of GBMs)
Temozolomide provides minimal additional benefit over radiation alone. Clinical trial enrolment (lomustine, bevacizumab, TTFields, immunotherapy) is particularly important for unmethylated tumours where standard treatment is inadequate.
Complete GBM Biomarker Reference Guide
A practical reference for every molecular marker that should appear in a comprehensive brain tumour pathology report.
| Biomarker | What It Tests | Why It Matters | Result Impact |
|---|---|---|---|
| MGMT promoter methylation | Methylation of MGMT repair enzyme promoter | Predicts temozolomide chemotherapy benefit | Methylated = TMZ works well; Unmethylated = consider trials |
| IDH1/IDH2 mutation | Isocitrate dehydrogenase gene mutation | Defines tumour grade and prognosis โ IDH-mutant gliomas are lower grade | Mutant = better prognosis, grade 2โ3 glioma; Wildtype = true GBM |
| 1p/19q co-deletion | Loss of chromosomal arms 1p and 19q | Confirms oligodendroglioma โ most chemo-sensitive brain tumour | Present (with IDH) = oligodendroglioma; Absent = astrocytoma |
| TERT promoter mutation | Telomerase reverse transcriptase promoter | Prognostic marker โ TERT + IDH-wildtype = worst prognosis | Present in most primary GBMs; with IDH = oligodendroglioma |
| EGFR amplification | Epidermal growth factor receptor gene amplification | Diagnostic marker for GBM โ not yet a targetable driver | Amplified in ~40% of GBMs โ relevant for trial eligibility |
| EGFRvIII deletion | Exon 2โ7 deletion mutation in EGFR | Targetable by some experimental therapies including CAR-T | Present in ~25% of GBMs โ relevant for vaccine and CAR-T trials |
| PTEN deletion | Tumour suppressor gene deletion | Prognostic โ associated with shorter survival and PI3K pathway activation | Lost in ~40% of GBMs โ relevant for PI3K inhibitor trials |
| H3K27M mutation | Histone H3 lysine 27 mutation | Defines diffuse midline glioma (DMG) โ separate from GBM | Present = DMG diagnosis โ ONC201 and specific trials apply |
| ATRX loss | ATRX chromatin remodelling gene | Marker of astrocytic lineage in IDH-mutant gliomas | Lost = IDH-mutant astrocytoma; Intact + IDH = oligodendroglioma |
How to Read Your Brain Tumour Pathology Report
Brain tumour pathology reports are complex โ follow these steps to identify the key information that determines your diagnosis and treatment options.
- 1
Find the WHO Diagnosis
The report should state a WHO 2021 integrated diagnosis โ e.g. 'Glioblastoma, IDH-wildtype, CNS WHO Grade 4' or 'Astrocytoma, IDH-mutant, Grade 3'.
- 2
Note the IDH Status
IDH-wildtype = true GBM, aggressive, median OS ~15 months. IDH-mutant = lower-grade glioma masquerading as GBM โ much better prognosis, different treatment.
- 3
Check MGMT Methylation
Find 'MGMT promoter methylation status: methylated/unmethylated'. This single result determines whether temozolomide chemotherapy is likely to help significantly.
- 4
Look for 1p/19q Co-deletion
If IDH-mutant and 1p/19q co-deleted = oligodendroglioma (most treatable). If IDH-mutant but 1p/19q intact = astrocytoma.
- 5
Note EGFR and H3K27M
EGFR amplification/EGFRvIII may determine clinical trial eligibility. H3K27M identifies diffuse midline glioma โ a different disease requiring different trials (ONC201).
Key Numbers: How Biomarkers Change Outcomes
- 21.7 moMedian OS โ MGMT methylated GBM on Stupp protocolvs 12.7 months in MGMT-unmethylated patients in the landmark EORTC 26981 trial.
- >5 yr5-year survival โ IDH-mutant grade 3 gliomaIDH-mutant gliomas have dramatically better prognosis than IDH-wildtype GBM โ different disease, different treatment.
- 45%GBMs with MGMT methylationApproximately 45% of newly diagnosed GBMs are MGMT-methylated and therefore most likely to benefit from temozolomide.
Frequently Asked Questions
Understanding Your Biomarkers
My report says IDH-wildtype โ does that mean I definitely have GBM?
IDH-wildtype combined with other markers (EGFR amplification, TERT mutation, chromosome 10 loss) meets WHO 2021 criteria for GBM even if the morphology appears lower-grade. Conversely, IDH-wildtype without these molecular features and a low-grade appearance may not behave like typical GBM. The integrated diagnosis in your report is what matters โ not the IDH result in isolation.
My MGMT is unmethylated โ should I still take temozolomide?
Most neuro-oncologists still give temozolomide to unmethylated GBM patients as part of the Stupp protocol, because the absolute benefit (though smaller) may still exist and there is no better proven alternative. However, for unmethylated patients, enrolment in clinical trials โ particularly those testing lomustine, immunotherapy, or TTFields โ is especially important given the limited benefit from standard chemotherapy.
My tumour shows H3K27M โ is this GBM?
H3K27M-mutant tumours are classified as Diffuse Midline Glioma (DMG) under WHO 2021 โ a separate diagnosis from GBM. DMGs arise in midline structures (thalamus, brainstem, spinal cord) and have a poor prognosis similar to GBM. Critically, ONC201 โ a specific drug for H3K27M-mutant DMG โ has shown remarkable activity in H3K27M-positive tumours and is available through trials. CancerFax can help identify ONC201 access.
Should I get a second opinion on my pathology?
Yes โ for brain tumours, a pathology second opinion at a high-volume neuro-oncology centre is strongly recommended. The 2021 WHO classification of brain tumours changed significantly, and not all pathology labs apply the integrated molecular criteria correctly. CancerFax can coordinate pathology slide review at specialist centres in China or India.
More from the Brain Cancer Resource Library
Explore related guides on glioblastoma treatment, clinical trials, and biomarker-guided therapy.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination โ travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Help Understanding Your Glioblastoma Pathology Report?
CancerFax reviews your complete pathology and molecular report, explains what each biomarker means for your specific case, and identifies whether your tumour profile opens access to clinical trials or targeted therapies not available at your current centre.
This content is for informational purposes only and does not constitute medical advice. Always consult a qualified oncologist before making treatment decisions.